PCM
IART icon

Penserra Capital Management’s Integra LifeSciences IART Stock Holding History

Penserra Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,106
Closed -$126K – 924
2019
Q3 		$126K Buy
+2,106
New +$125K 0.01% 490
2018
Q4 		– Sell
-820
Closed -$54K – 702
2018
Q3 		$54K Buy
+820
New +$51K ﹤0.01% 521

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Penserra Capital Management's IART Position: Q4 2019 in Review

Penserra Capital Management sold out of Integra LifeSciences (IART) in Q4 2019, closing a stake of 2,106 shares — an estimated $126K sold.

Penserra Capital Management first reported a position in IART in Q3 2018 and held it in 2 quarters. The position peaked at $126K in Q3 2019. 279 funds tracked by Wall St. Rank hold IART as of Q4 2019.

  • Penserra Capital Management reported no remaining Integra LifeSciences position as of Q4 2019 after selling out during the quarter.
  • Penserra Capital Management sold 2,106 Integra LifeSciences shares in Q4 2019, an estimated $126K.
  • Penserra Capital Management first reported a position in Integra LifeSciences in Q3 2018 and held it in 2 quarters.
  • Penserra Capital Management's Integra LifeSciences position peaked at $126K in Q3 2019.
  • 279 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2019.

Based on Penserra Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.